Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy
-
Register
- Member - Free!
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Target Audience:
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer.
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs.
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
For faculty and Planning Committee disclosures, please view the 'Overview' tab specific to each session.
-
Contains 4 Component(s)
This session provides an overview of guideline development in the community setting for the utilization of BsAbs in patients.
You must have an ACCC account in order to register for this course/webinar/webinar series.
If You DO NOT Have An ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!
If You Have An ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to this course/webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this course/webinar . For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Release Date: July 26, 2024
Expiration Date: July 26, 2025
Overview:
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Beginning in 2020, the Association of Community Cancer Centers (ACCC) initiated research and education focused on the utilization of BsAbs in the community oncology setting. Findings from an ACCC survey illuminated several barriers to using BsAbs in the community setting. Among these, 59% of survey respondents indicated that they have experienced barriers when caring for patients treated with BsAbs.
Target Audience:
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption, and use of bispecific antibodies for the treatment of cancer
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes and ensure safety for patients being treated with bispecific antibodies
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-119-H01-P. The activity is available for CE credit through July 26, 2025.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: Caroline Jones, PharmD, Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, Samantha Steinert, RN, and the staff of Physicians’ Education Resource®, LLC.
Firas El Chaer, MD - Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie, MorphoSys, ACCC, Other: Travel grant, Dava Oncology
Amelia Hodson, AG-ACNP - Consultant: Geron
Murali Janakiram, MD, MS - Speaker: Janssen
Firas El Chaer, MD
Assistant Professor, UVA Health
Dr. El Chaer is an Assistant Professor of Medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis, and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms.
Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai, in Englewood, New Jersey, where he served as chief resident from 2013 - 2014. He then completed a fellowship in infectious diseases for immune-compromised cancer patients at the combined program of Baylor College of Medicine and MD Anderson Cancer Center in Houston, Texas.
Dr. El Chaer pursued a fellowship in hematology and oncology with a focus on blood disorders and also completed a built-in fellowship in stem cell transplantation at the University of Maryland School of Medicine, where he served as a chief fellow from 2018 - 2019.
Amelia Hodson, AG-ACNP
UVA Health
Amelia S. Hodson, AG-ACNP, is a board-certified nurse practitioner, who cares for hospitalized patients undergoing stem cell transplant for blood and other cancers.
She began her career at UVA in 2007 as a registered nurse. She has specialized in oncology (cancer) since 2015. She spent three years as a clinical research nurse in malignant hematology (blood disorders) before transitioning to the hospital unit for oncology and stem cell transplant patients.
She earned her RN degree at UVA and her master’s degree in nursing at Maryville University. She is board-certified by the American Nurses Credentialing Center as an adult geriatric acute care nurse practitioner.
Caroline Jones
PharmD, Clinical Pharmacist, Leukemia/MDS
UVA Health
Caroline Jones, PharmD, is a clinical pharmacist in hematology/oncology at the University of Virginia Health System. Dr. Jones practices as the outpatient clinical pharmacist for malignant hematology, specializing in leukemia and bone marrow failure disorders. Dr. Jones received her Doctor of Pharmacy from Virginia Commonwealth University School of Pharmacy. Following pharmacy school, she completed an ASHP accredited PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at the University of Virginia Health System
Sam Steinert
RN
UVA Health
Sam earned her Bachelor's in Public Health Studies from Syracuse University and then her BSN from the University of Rochester in 2019. Her first two years of nursing were spent at the University of Rochester Wilmot Cancer Center as an impatient Bone Marrow Transplant nurse. Sam took a travel nursing position at the University of Virginia and fell in love with the patients and UVA. She now works as a Care Coordinating RN for the Malignant Hematology department. Sam is passionate about ensuring the complex care needs are consistently met for all patients she serves.
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
-
Contains 4 Component(s)
This session provides an overview of the utilization of BsAbs in patients with follicular lymphoma.
You must have an ACCC account in order to register for Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma).
If You DO NOT Have An ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!
If You Have An ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma). For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Release date: July 3, 2024
Expiration date: July 3, 2025
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Target Audience:
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer.
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs.
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies.
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-118-H01-P. The activity is available for CE credit through July 3, 2025.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: Justina Kiernan, PA, Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, and the staff of Physicians’ Education Resource®, LLC.
Firas El Chaer, MD - Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie, MorphoSys, ACCC, Other: Travel grant, Dava Oncology
Amelia Hodson, AG-ACNP - Consultant: Geron
Murali Janakiram, MD, MS – Speaker: Janssen
Pallawi Torka, MD - Consultant: Genetech, Lilly USA, Genmab, ADC Therapeutics, TG Therapeutics, Seagen (all relationships have ended)
Pallawi Torka, MD
Memorial Sloan Kettering Cancer Center
Dr. Torka is a hematologist-oncologist who cares for patients with various kinds of lymphoma, as well as chronic lymphocytic leukemia (CLL). I think of myself as a clinician, researcher, and educator in that order, with my personal mantra being “treat every patient like family.”
No two patients are the same, so their treatment plans should not be the same either. When I meet a new patient for the first time, I go over their whole story in detail and analyze every detail of their case to ensure that we come up with the best plan of care together. I believe that the best care plans incorporate not only cutting-edge science, but also the patient’s individual beliefs. Hearing “you have cancer” is difficult; my goal is to walk the complicated and often confusing road with my patients and their families, doing everything I can to make the journey easier.
Justina Kiernan, MPAS, PA-C
Memorial Sloan Kettering Cancer Center
Justina Kiernan is a hematology/oncology PA at Memorial Sloan Kettering Cancer Center in New York, NY. She earned her degree from Mercy College.
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
-
Contains 4 Component(s)
This session provides an overview of the utilization of BsAbs in patients with diffuse large b-cell lymphomas
You must have an ACCC account in order to register for Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma).
If You DO NOT Have An ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!
If You Have An ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma). For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Release date: July 3, 2024
Expiration date: July 3, 2025
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Beginning in 2020, the Association of Community Cancer Centers (ACCC) initiated research and education focused on the utilization of BsAbs in the community oncology setting. Findings from an ACCC survey illuminated several barriers to using BsAbs in the community setting. Among these, 59% of survey respondents indicated that they have experienced barriers when caring for patients treated with BsAbs.
Target Audience:
The target audience for the initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer.
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs.
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies.
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-117-H01-P. The activity is available for CE credit through July 3, 2025.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, and the staff of Physicians’ Education Resource®, LLC.
Firas El Chaer, MD - Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie, MorphoSys, ACCC, Other: Travel grant, Dava Oncology
Kirollos Hanna, PharmD, BCPS, BCOP, FACC – Consultant: Seagen, Beigene, BMS; Speakers’ Bureau: Seagen, Beigene, Exelixis, BMS
Amelia Hodson, AG-ACNP - Consultant: Geron
Murali Janakiram, MD, MS – Speaker: Janssen
Joanna Rhodes, MD - Grant/Research Support: Abbvie, Beigene, Janssen, Loxo Oncology, Consultant: Abbvie, Beigene, AstraZeneca, Genentech, Janssen, Genmab, SeaGen, Loxo Oncology
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his doctorate of pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove.
Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, Drugs, JOPP, AJMC and JHOP. He is also an active member of the Hematology/Oncology Pharmacy Association, Association of Community Cancer Centers, Patient-Centered Outcomes Research Institute, Aplastic Anemia and MDS International Foundation and the American College of Clinical Pharmacy.
Joanna Rhodes, MD, MSCE
Rutgers Cancer Institute
Dr. Rhodes received her BA from Wesleyan University and then a Masters in Medical Sciences at Boston University. After this, she worked at Dana Farber Cancer Institute as a Clinical Research Coordinator, and knew after that experience she wanted to pursue a career in hematologic malignancies. Dr. Rhodes completed medical training at Stony Brook School of Medicine and subsequently did her residency training in Internal Medicine at New York Presbyterian Weill Cornell. She then went to the University of Pennsylvania for Hematology/Oncology fellowship where she also received a Masters of Science in Clinical Epidemiology with a focus in Pharmacoepidemiology. In fellowship, Dr. Rhodes sub-specialized in the care of CLL/lymphoma patients and have have dedicated my career to caring for these patients since.
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
-
Contains 4 Component(s)
This session provides an overview of the utilization of BsAbs in patients with multiple myeloma.
You must have an ACCC account in order to register for Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma).
If You DO NOT Have An ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!
If You Have An ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this Session Two: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Multiple Myeloma). For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Release date: May 23, 2024
Expiration date: May 23, 2025
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Target Audience:
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer.
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs.
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies.
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-116-H01-P. The activity is available for CE credit through May 23, 2025.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, and the staff of Physicians’ Education Resource®, LLC.
Firas El Chaer, MD - Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie, MorphoSys, ACCC, Other: Travel grant, Dava Oncology
Kirollos Hanna, PharmD, BCPS, BCOP, FACC – Consultant: Seagen, Beigene, BMS; Speakers’ Bureau: Seagen, Beigene, Exelixis, BMS
Amelia Hodson, AG-ACNP - Consultant: Geron
Murali Janakiram, MD, MS – Speaker: Janssen
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his doctorate of pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove.
Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, Drugs, JOPP, AJMC and JHOP. He is also an active member of the Hematology/Oncology Pharmacy Association, Association of Community Cancer Centers, Patient-Centered Outcomes Research Institute, Aplastic Anemia and MDS International Foundation and the American College of Clinical Pharmacy.
Murali Janakiram, MBBS, MS
Assistant Professor, Division of Myeloma
City of Hope Medical Center
Murali Janakiram, MD, MS, is a board-certified hematologist/oncologist whose clinical expertise is in multiple myeloma and aggressive lymphomas (e.g., T-cell lymphoma, adult T-cell leukemia/lymphoma, viral associated lymphomas, B-cell lymphomas, and transformed lymphoma). Dr. Janakiram focuses on delivering the best clinical care to the patient, which includes new FDA-approved drugs, access to clinical trial drugs, cellular therapy, and bone marrow transplant.
Every patient is different, and Dr. Janakiram helps patients with lymphoma and myeloma choose the best option. His research interests are in multiple myeloma, T-cell lymphoma, and cellular therapy in lymphoma. In cellular therapy, Dr. Janakiram has extensive experience in taking care and successfully treating patients with CAR T-cell therapy.
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
-
Contains 4 Component(s)
This session provides an overview of the utilization of BsAbs in patients with cancer.
You must have an ACCC account in order to register for Session One: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Overview).
If You DO NOT Have An ACCC Account:
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
- Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
- The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!
If You Have An ACCC Account:
- Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
- You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!
PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this Session One: Project ECHO - Evolving Role of Bispecific Antibodies as Cancer Therapy (Overview). For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Release date: May 23, 2024
Expiration date: May 23, 2025
Bispecific antibodies (BsAbs), an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with BsAbs, clinicians must understand the unique pharmacology and potential clinical and logistical challenges of these agents. Successful administration of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Target Audience:
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives:
At the end of this educational activity, participants should be able to:
- Address barriers to the awareness, preparedness, adoption and use of BsAbs for the treatment of cancer.
- Improve coordination and communication between community hospitals and academic centers to optimize outcomes for patients beings treated with BsAbs.
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies.
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource®, LLC and the Association of Cancer Care Centers (ACCC). Physicians' Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-24-115-H01-P. The activity is available for CE credit through May 23, 2025.
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Genentech.
Disclosures and Conflict of Interest (COI) Mitigation
PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: Molly Kisiel, MSN, FNP-BC, Mary Stanley, LMSW, PMP, and the staff of Physicians’ Education Resource®, LLC.
Firas El Chaer, MD – Consultant: SPD Oncology, Amgen, CTI Biopharma, AbbVie, MorphoSys, ACCC; Travel Grant: Dava Oncology
Kirollos Hanna, PharmD, BCPS, BCOP, FACC – Consultant: Seagen, Beigene, BMS; Speakers’ Bureau: Seagen, Beigene, Exelixis, BMS
Amelia Hodson, MSN, AG-ACNP – Consultant: Geron
Murali Janakiram, MD, MS – Speaker: Janssen
Firas El Chaer, MD
Assistant Professor, UVA Health
Dr. El Chaer is an Assistant Professor of Medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis, and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms.
Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai, in Englewood, New Jersey, where he served as chief resident from 2013 - 2014. He then completed a fellowship in infectious diseases for immune-compromised cancer patients at the combined program of Baylor College of Medicine and MD Anderson Cancer Center in Houston, Texas.
Dr. El Chaer pursued a fellowship in hematology and oncology with a focus on blood disorders and also completed a built-in fellowship in stem cell transplantation at the University of Maryland School of Medicine, where he served as a chief fellow from 2018 - 2019.
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his doctorate of pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove.
Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, Drugs, JOPP, AJMC and JHOP. He is also an active member of the Hematology/Oncology Pharmacy Association, Association of Community Cancer Centers, Patient-Centered Outcomes Research Institute, Aplastic Anemia and MDS International Foundation and the American College of Clinical Pharmacy.
Amelia Hodson, AG-ACNP
UVA Health
Amelia S. Hodson, AG-ACNP, is a board-certified nurse practitioner, who cares for hospitalized patients undergoing stem cell transplant for blood and other cancers.
She began her career at UVA in 2007 as a registered nurse. She has specialized in oncology (cancer) since 2015. She spent three years as a clinical research nurse in malignant hematology (blood disorders) before transitioning to the hospital unit for oncology and stem cell transplant patients.
She earned her RN degree at UVA and her master’s degree in nursing at Maryville University. She is board-certified by the American Nurses Credentialing Center as an adult geriatric acute care nurse practitioner.
- To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
